KBC Group
CRSP icon

KBC Group’s CRISPR Therapeutics CRSP Stock Holding History

KBC Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.48M Buy
117,169
+322
+0.3% +$17.4K 0.01% 461
2026
Q2 		$6.37M Hold
116,847
– – 0.01% 456
2026
Q1 		$5.56M Buy
116,847
+113,997
+4,000% +$6.01M 0.01% 456
2025
Q4 		$149K Buy
2,850
+626
+28% +$37.5K ﹤0.01% 1044
2025
Q3 		$144K Hold
2,224
– – ﹤0.01% 1053
2025
Q2 		$108K Sell
2,224
-1,526
-41% -$59.1K ﹤0.01% 1148
2025
Q1 		$128K Sell
3,750
-56,764
-94% -$2.41M ﹤0.01% 1344
2024
Q4 		$2.38M Buy
60,514
+57,696
+2,047% +$2.72M 0.01% 665
2024
Q3 		$132K Buy
2,818
+860
+44% +$43.6K ﹤0.01% 1118
2024
Q2 		$106K Buy
1,958
+351
+22% +$20.3K ﹤0.01% 1129
2024
Q1 		$110K Hold
1,607
– – ﹤0.01% 1075
2023
Q4 		$101K Hold
1,607
– – ﹤0.01% 1063
2023
Q3 		$73K Buy
+1,607
New +$83K ﹤0.01% 1157
2021
Q4 		– Sell
-600
Closed -$67K – 1295
2021
Q3 		$67K Hold
600
– – ﹤0.01% 1211
2021
Q2 		$97K Hold
600
– – ﹤0.01% 1176
2021
Q1 		$73K Hold
600
– – ﹤0.01% 1215
2020
Q4 		$92K Sell
600
-600
-50% -$70.9K ﹤0.01% 1167
2020
Q3 		$100K Hold
1,200
– – ﹤0.01% 1118
2020
Q2 		$88K Hold
1,200
– – ﹤0.01% 1166
2020
Q1 		$51K Hold
1,200
– – ﹤0.01% 1195
2019
Q4 		$73K Buy
1,200
+1,035
+627% +$56.5K ﹤0.01% 1385
2019
Q3 		$7K Sell
165
-1,035
-86% -$49.5K ﹤0.01% 1461
2019
Q2 		$57K Hold
1,200
– – ﹤0.01% 1345
2019
Q1 		$43K Hold
1,200
– – ﹤0.01% 1328
2018
Q4 		$34K Hold
1,200
– – ﹤0.01% 1243
2018
Q3 		$53K Hold
1,200
– – ﹤0.01% 1327
2018
Q2 		$71K Sell
1,200
-500
-29% -$28.5K ﹤0.01% 1204
2018
Q1 		$78K Buy
1,700
+1,000
+143% +$41.3K ﹤0.01% 1195
2017
Q4 		$16K Buy
+700
New +$13.3K ﹤0.01% 1242

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Slow Capital
Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

KBC Group's CRSP Position: Q3 2026 in Review

KBC Group increased its CRISPR Therapeutics (CRSP) stake by 0.28% in Q3 2026, buying an estimated $17.4K and bringing the position to 117,169 shares worth $6.48M. The position accounts for 0.01% of the portfolio, ranked #461.

KBC Group first reported a position in CRSP in Q4 2017 and has held it in 29 quarters since. 159 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • KBC Group held 117,169 shares of CRISPR Therapeutics worth $6.48M as of Q3 2026.
  • KBC Group bought 322 CRISPR Therapeutics shares in Q3 2026, an estimated $17.4K.
  • CRISPR Therapeutics made up 0.01% of KBC Group's portfolio in Q3 2026, its #461 holding.
  • KBC Group first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 29 quarters since.
  • 159 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.